Corcept Therapeutics Securities Fraud Class Action
Corcept Therapeutics · Relacorilant and related securities
Investors allege that Corcept Therapeutics and other defendants misrepresented the strength of clinical evidence supporting relacorilant and the likelihood that the related New Drug Application would be approved, causing losses when the alleged risks became known. A securities class action has been filed, but the class has not been certified; the current procedural stage is otherwise not specified.
Case updates and reports
How to participate
Class action case submission
Purchasers of Corcept common stock between October 31, 2024 and December 30, 2025, inclusive, were invited to contact counsel regarding the lawsuit.
- Type
- Law Firm Signup
- Law firm signup
- Deadline passed
- Reported proof requirement
- Unclear
Lead Plaintiff Application
Investors who purchased or otherwise acquired Corcept shares between October 31, 2024 and December 30, 2025, inclusive, could seek appointment as lead plaintiff.
- Type
- Law Firm Signup
- Law firm signup
- Deadline passed
- Reported proof requirement
- Unclear
Lead Plaintiff Application
Investors who suffered losses related to Corcept Therapeutics securities may have sought appointment as lead plaintiff in the securities fraud class action.
- Type
- Lead Plaintiff
- Lead plaintiff status
- Deadline passed
Discuss Legal Rights
Investors who purchased or acquired Corcept common stock between October 31, 2024, and December 30, 2025 are invited to discuss their legal rights.
- Type
- Law Firm Signup
- Law firm signup
- Unknown
Absent Class Member Participation
The announcement states that class members need not take action at this time and may remain absent members of the class action.
- Type
- Other
- Availability
- No action required